Retinitis Pigmentosa (RP)
Vascular/Metabolic Retinal Conditions
Diabetic Retinopathy (DR)
Optic Nerve Conditions
jCyte’s lead program, jCell, is a first-in-class, minimally-invasive intravitreal injection in late-stage clinical development for retinitis pigmentosa (RP) and other dystrophies.
There is currently no effective treatment for RP, and once photoreceptors are lost, they do not regenerate. The promising results from the Phase 2b study suggest that jCell therapy in patients with retinitis pigmentosa can result in significant slowing of visual deterioration and an improvement in function of existing photoreceptors. The primary goal of jCell therapy is to preserve, and potentially improve, vision by intervening in the disease at a time when dystrophic photoreceptors can be protected and reactivated.
Our animal models indicate that selectively targeting photoreceptors in vascular retinal conditions, such as diabetic retinopathy, and optic nerve conditions, such as glaucoma, as well as other optic neuropathies, holds great therapeutic promise. By selectively targeting photoreceptors in the eye, jCyte aims to target many blinding diseases through jCell’s novel mechanism of action.
We are eager to initiate a pivotal clinical trial of our lead product candidate, jCell, as soon as possible as a potential treatment option for patients with retinitis pigmentosa, based on promising Phase 2b results which were announced in July 2020.
Retinitis pigmentosa is a degenerative retinal disease that progressively destroys the rod and cone photoreceptors in the retina. It often strikes people in their teens, with many patients rendered legally blind by middle age. Worldwide, an estimated 1.9 million people suffer from the disease, including approximately 100,000 people in the U.S., making it the leading cause of inheritable blindness.
If you are interested in learning more or participating in our upcoming clinical trial, please contact Jennifer Clinton at 617-420-8850 or email us at email@example.com.